Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250
Darmstadt
64293
Germany
Tel: 49-6151-720
Fax: 49-6151-722000
Website: https://www.emdgroup.com/en
Email: service@emdgroup.com
646 articles about Merck KGaA, Darmstadt, Germany
-
MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea
3/20/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.
-
The company announced Thursday it terminated its BTK inhibitor evobrutinib for multiple sclerosis, which did not meet the primary endpoints in two late-stage trials.
-
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
3/4/2024
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) today announced it has entered into a license and collaboration agreement with Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline.
-
EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits
2/29/2024
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of two new post-hoc analyses of tertiary endpoints from the MAGNIFY-MS study, a Phase IV, prospective, open-label study evaluating the efficacy and safety of MAVENCLAD® tablets in highly active relapsing multiple sclerosis.
-
On a Quest To Make All Chemistry Green Chemistry
2/6/2024
For years there wasn't an easy way. Then, in 2019, a team of chemists and bioinformatic experts from MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, debuted a new tool, known as the DOZN™ tool.
-
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
1/22/2024
EMD Serono today announced new real-world data that continue to reinforce the JAVELIN Bladder regimen of first-line platinum-based chemotherapy followed by BAVENCIO® (avelumab) maintenance as a standard of care for eligible patients with locally advanced or metastatic urothelial carcinoma (UC) who do not progress on first-line chemotherapy.
-
Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna
1/4/2024
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a licensing agreement with Inspirna, Inc. (New York, NY) for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds.
-
Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid (RGX-202)
1/4/2024
Inspirna, Inc.announced today a licensing agreement with Merck KGaA, Darmstadt, Germany, for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, currently in development for RAS mutated (RASm) second-line (2L) advanced or metastatic colorectal cancer (mCRC) and SLC6a8 targeting follow-on compounds.
-
In two late-stage trials, the experimental oral drug evobrutinib was unable to significantly reduce annualized relapse rates in MS patients compared with Sanofi’s Aubagio tablets.
-
Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
12/5/2023
Merck KGaA, Darmstadt, Germany today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (0.11 vs. 0.11 in evolutionRMS 1 and 0.15 for evobrutinib and 0.14 for teriflunomide in evolutionRMS 2, p=NS in both trials)
-
MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis
12/5/2023
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, launched its AIDDISON™ drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability through Synthia™ retrosynthesis software application programing interface integration.
-
Merck KGaA, Darmstadt, Germany Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib
12/4/2023
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a license agreement with Abbisko Therapeutics Co. Ltd., Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT).
-
EMD Serono Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District
11/14/2023
EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced that it plans to move its U.S. Healthcare headquarters, currently located in Rockland, Mass., to Boston’s Seaport district.
-
MilliporeSigma Launches ChemisTwin™, First Ever Digital Reference Material Platform for Analytical Testing
11/14/2023
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, has launched ChemisTwinTM, the first digital reference materials platform that can perform automatic analysis of samples' purity, identification, and degradation of compounds through calibrated algorithm-based digital references.
-
Life Science Business of Merck KGaA, Darmstadt, Germany, Wins Sustainability Excellence Award
11/9/2023
The Life Science business of Merck KGaA, Darmstadt, Germany was named a World Sustainability Awards 2023 winner at the World Sustainability Awards 2023.
-
Huma signs partnership with Merck KGaA, Darmstadt, Germany to support cancer care
11/7/2023
Huma Therapeutics, a leading global digital health company, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a partnership to develop a digital solution that aims to help cancer patients better understand and manage their conditions and treatment.
-
Unpacking SMASH Packaging 2.0, MilliporeSigma's Newest Plan To Reduce the Impact of Packaging
11/1/2023
The process began in 2019 when the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, launched SMASH Packaging.
-
Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
10/30/2023
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd.
-
Hengrui Pharma Partners with Merck KGaA, Darmstadt, Germany, to Advance Innovative Cancer Therapies
10/30/2023
Jiangsu Hengrui Pharmaceuticals Co., Ltd announced a licensing agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, for its next-generation potent and selective PARP1 inhibitor, HRS-1167.
-
Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS
10/11/2023
Data from the ongoing Phase II open-label extension (OLE) study of evobrutinib show sustained clinical efficacy and a safety profile that remains consistent with that previously reported over five years of therapy - the longest follow-up of any Bruton’s tyrosine kinase inhibitor (BTKi) in multiple sclerosis (MS) studies Additional Phase II OLE data show significant and clinically meaningful improvements on mental health and quality of life measures in study participants with relapsing